Ernexa Therapeutics (ERNA) Expected to Announce Earnings on Wednesday

Ernexa Therapeutics (NASDAQ:ERNA) is anticipated to issue its results after the market closes on Wednesday, August 12th. Analysts expect the company to post earnings of ($3.30) per share for the quarter.

Ernexa Therapeutics (NASDAQ:ERNA) last posted its earnings results on Monday, May 11th. The company reported ($6.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00). On average, analysts expect Ernexa Therapeutics to post $-18 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ernexa Therapeutics Stock Up 28.1%

Ernexa Therapeutics stock opened at $4.42 on Wednesday. Ernexa Therapeutics has a 52-week low of $3.18 and a 52-week high of $71.50. The firm has a market capitalization of $5.17 million, a price-to-earnings ratio of -0.17 and a beta of 2.57. The firm has a 50-day moving average price of $6.29 and a two-hundred day moving average price of $9.25.

Analyst Upgrades and Downgrades

ERNA has been the topic of a number of recent analyst reports. Zacks Research raised Ernexa Therapeutics to a “hold” rating in a report on Monday, May 11th. Brookline Capital Markets initiated coverage on Ernexa Therapeutics in a report on Thursday, May 7th. They issued a “buy” rating and a $30.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen raised Ernexa Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $30.00.

Institutional Investors Weigh In On Ernexa Therapeutics

An institutional investor recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new position in Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 70.55% of the company’s stock.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.